The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,774.50
Bid: 1,774.00
Ask: 1,774.50
Change: -3.50 (-0.20%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday newspaper round-up: De La Rue, Tesco, Glaxo Smith Kline

Mon, 23rd Jul 2018 06:40

(Sharecast News) - The hedge fund pushing for change at passport and banknote maker De La Rue has increased its stake and ramped-up pressure on the boss to overhaul the firm. Crystal Amber is now understood to control about 4 per cent of the British company, up from 3.1 per cent following a high volume of trades on Friday. The activist fund is calling on De La Rue's management to come up with a strategy that will prepare it for the future by focusing more on selling its technology. - The Daily MailTesco is set to launch a chain of discount shops to take on cut-price German retailers Aldi and Lidl at their own game. The supermarket giant has earmarked as many as 60 existing stores to transform into a low-price chain expected to operate under a new brand name. Sources speculated that the stores may be called Jack's - a reference to Tesco founder Jack Cohen - because an obscure Tesco subsidiary recently tried to register the name as a trademark. - The Daily MailIn a strategy update this week, Glaxo is expected to outline plans to focus on developing blockbuster cancer drugs as it rebuilds its portfolio in the medicines industry's most lucrative market four years after it largely, and contentiously, exited the area via a multibillion-dollar asset swap with Novartis, a Swiss rival. Ms Walmsley will be joined at a presentation to the City on Wednesday by Hal Barron, Glaxo's new chief scientific officer and head of research and development, who has been reviewing the drugs pipeline for the past six months. - The TimesTheresa May will chair a cabinet meeting in the north-east of England as she starts a summer campaign intended to gain public support for her much-criticised Chequers Brexit plan. The visit on Monday is intended primarily to show the government's ongoing support for the "northern powerhouse" concept, and May will confirm that up to £780m is being set aside for a pre-planned east coast mainline upgrade and that the is to go ahead. - The GuardianPresident Trump's efforts to neutralise the nuclear threat posed by North Korea are in danger of running aground as the communist state cancels key meetings and returns to its belligerent rhetoric. [...] However, US diplomats have since made it known that their counterparts in Pyongyang have refused to engage in meaningful discussions. American intelligence officials have told The Washington Post that the North is working to conceal key aspects of its nuclear programme and that a missile-engine testing facility that Mr Trump said would be destroyed remains intact. - The TimesBritain will "thrive" even if there is no Brexit deal, Dominic Raab has said, as his predecessor David Davis called on the Prime Minister to "reset" her Brexit plan and prepare a "reserve parachute" in case no agreement is reached. Mr Raab said there was "tremendous pressure" on the EU to secure a deal as he branded his counterparts "irresponsible" for failing to reassure British citizens living abroad about their rights after Brexit. - The Daily TelegraphA second investment fund has been set up in Ireland by the City firm co-founded by Jacob Rees-Mogg, after it warned earlier this year about the financial dangers of the sort of hard Brexit favoured by the Conservative MP. The fund, which is backed by $50m (£38m) in seed money from the Swedish national pension plan, was created to meet demand from international investors, according to Somerset Capital Management (SCM). - The Guardian
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.